Bivalent Diazo Smac Mimetics for IAP Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies face resistance due to cancer cells' defects in apoptosis machinery, leading to inefficacy of chemotherapeutic agents and radiation, with a need for agents that can selectively sensitize tumor cells to apoptosis-inducing drugs like TRAIL without affecting normal cells.
Innovation Solution
Development of bivalent diazo bicyclic Smac mimetics that inhibit Inhibitor of Apoptosis Proteins (IAPs), specifically targeting XIAP to enhance the sensitivity of cancer cells to apoptosis-inducing agents like TRAIL, thereby overcoming resistance and improving treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cancer cells develop defects in apoptosis machinery, then resistance to chemotherapeutic agents and radiation increases, but the effectiveness of current cancer therapies decreases
Solution Approach 1:
The patent uses Smac mimetics as intermediary molecules that bridge the gap between apoptotic stimuli and IAP proteins. These mimetics bind to IAPs (specifically XIAP) to prevent their inhibitory action on caspases, thereby restoring apoptosis sensitivity in resistant cancer cells without directly killing them like traditional chemotherapies
Solution Approach 2:
The invention changes the molecular parameter by targeting IAP proteins rather than directly attacking DNA or membranes. By modifying the interaction at the caspase-IAP level, the patent overcomes resistance mechanisms that have evolved from direct apoptotic pathway attacks
2Adaptability or versatility
If bivalent diazo bicyclic Smac mimetics are designed to specifically inhibit IAPs, then selectivity for cancer cells improves, but the complexity of the molecular structure increases
Solution Approach 1:
The Smac mimetic molecule is segmented into distinct functional components: a diazo bicyclic core structure that provides binding affinity for IAPs, and tethering groups that confer selectivity and cellular penetration properties. This segmentation allows each component to be optimized independently
Solution Approach 2:
The patent creates a composite molecular structure combining diazo chemistry with bicyclic frameworks and various tethering moieties. This composite design achieves high selectivity for IAPs while maintaining reasonable pharmacological properties, balancing specificity with drug-likeness
3Productivity
If Smac mimetics are used to sensitize cancer cells to apoptosis, then the effectiveness of apoptosis-inducing drugs is enhanced, but potential toxicity to normal cells may increase
Solution Approach 1:
The Smac mimetics exhibit local quality by specifically targeting IAP proteins that are overexpressed in cancer cells. The bivalent diazo bicyclic structure provides selective binding to XIAP and other IAPs, creating a localized effect that enhances apoptosis in cancer cells while minimizing off-target effects on normal cells with different IAP expression profiles
Data Source
AI summary
The invention relates to diazo bicyclic Smac mimetics that are tethered through a covalent linker to give a bivalent species. Bivalent diazo bicyclic Smac mimetics function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs). The invention also relates to the use of bivalent diazo bicyclic Smac mimetics for inducing or sensitizing cells to the induction of apoptotic cell death. Thus, compounds of the invention are useful in the treatment, amelioration, or prevention of hyperproliferative diseases such as cancer.